Key Highlights
- Novartis shares traded higher following Phase 3 results for remibrutinib in multiple sclerosis.
- The data showed a significant reduction in relapses and brain lesions compared to Sanofi's teriflunomide.
- The results bolster Novartis's BTK inhibitor franchise.
- The company separately halted rap-cel trials for autoimmune diseases after three patient fatalities linked to a rare immune response.
Novartis AG (NYSE: NVS) shares traded higher following Phase 3 results for remibrutinib in multiple sclerosis, which demonstrated a significant reduction in relapses and brain lesions compared to Sanofi's teriflunomide.
What Happened
While the data bolster Novartis's BTK inhibitor franchise, the company separately halted rap-cel trials for autoimmune diseases after three patient fatalities linked to a rare immune response.
Market Reaction
Shares rose as investors weighed the positive remibrutinib data more heavily than the separate halt of the rap-cel program, which affects a different part of Novartis's broader pipeline.
Outlook
Continued development of the BTK inhibitor Franchise following the remibrutinib data, alongside further disclosure on the rap-cel trial halt, are likely to remain relevant for Novartis's pipeline narrative going forward.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.